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OBJECTIVE — Dapagliﬂozin, a highly selective inhibitor of the renal sodium-glucose co-
transporter-2, increases urinary excretion of glucose and lowers plasma glucose levels in an
insulin-independent manner. We evaluated the efﬁcacy and safety of dapagliﬂozin in treatment-
naive patients with type 2 diabetes.
RESEARCH DESIGN AND METHODS — This was a 24-week parallel-group, dou-
ble-blind, placebo-controlled phase 3 trial. Patients with A1C 7.0–10% (n  485) were
randomly assigned to one of seven arms to receive once-daily placebo or 2.5, 5, or 10 mg
dapagliﬂozin once daily in the morning (main cohort) or evening (exploratory cohort).
Patients with A1C 10.1–12% (high-A1C exploratory cohort; n  73) were randomly as-
signed1:1toreceiveblindedtreatmentwithamorningdoseof5or10mg/daydapagliﬂozin.
The primary end point was change from baseline in A1C in the main cohort, statistically
tested using an ANCOVA.
RESULTS — In the main cohort, mean A1C changes from baseline at week 24 were 0.23%
with placebo and 0.58, 0.77 (P  0.0005 vs. placebo), and 0.89% (P  0.0001 vs.
placebo) with 2.5, 5, and 10 mg dapagliﬂozin, respectively. Signs, symptoms, and other reports
suggestive of urinary tract infections and genital infection were more frequently noted in the
dapagliﬂozin arms. There were no major episodes of hypoglycemia. Data from exploratory
cohorts were consistent with these results.
CONCLUSIONS — Dapagliﬂozin lowered hyperglycemia in treatment-naive patients with
newlydiagnosedtype2diabetes.Thenearabsenceofhypoglycemiaandaninsulin-independent
mechanismofactionmakedapagliﬂozinauniqueadditiontoexistingtreatmentoptionsfortype
2 diabetes.
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T
he need for optimal management of
glycemia in patients with type 2 di-
abetes has long been recognized,
owing to the well-established association
between sustained hyperglycemia and se-
rious microvascular complications in-
cluding retinopathy, neuropathy, and
nephropathy (1). However, because met-
abolic risk factors frequently occur as a
cluster,itisdifﬁculttocontrolglycemiain
patientswithtype2diabeteswithoutneg-
atively affecting one or more of the asso-
ciated risk factors of hypertension,
obesity, and hyperlipidemia. This fact is
exempliﬁed by the treatment-limiting
side effects of many available antidiabetes
agents, particularly in patients with a
longer duration of disease (2–5). Sulfo-
nylureas, thiazolidinediones, and insulin
are all associated with weight gain in pa-
tientswithdiabetes(6,7).Negativeeffects
on associated metabolic risk factors are
not limited to antidiabetes agents; as an
example, treatment of hypertension with
thiazides is associated with increased uric
acid levels and a worsening of hypergly-
cemia (8–10). In addition to the deleteri-
ouseffectonmetaboliccomorbiditiesand
for some agents an increased risk of hy-
poglycemia, treatment with most antidia-
betes agents is further confounded by a
loss of efﬁcacy over time, in part due to
the progressive worsening of diabetes
characterized by insulin resistance and
impaired glucose-stimulated insulin
secretion (11).
An on-going effort to identify new
treatmentstrategiesfordiabeteshasledto
thedevelopmentofdapagliﬂozin,theﬁrst
in a class of compounds referred to as so-
dium-glucose cotransporter 2 (SGLT2)
inhibitors.SGLT2islocatedalmostexclu-
sively in the kidney proximal tubules
where it reabsorbs most of the 1 8 0go f
glucose that is ﬁltered through the glo-
meruli each day. Dapagliﬂozin is a highly
selective and reversible inhibitor of
SGLT2. A prolonged pharmacokinetic
half-life due to the C-aryl glucoside-
derived chemical structure, as well as a
nearly 3,000-fold selectivity for SGLT2
versus SGLT1, make it possible for dapa-
gliﬂozin to be administered in an unmod-
iﬁed oral form without affecting SGLT1-
mediated glucose transport in other
tissues (12–14). Dapagliﬂozin can inhibit
up to one-half of the ﬁltered glucose from
being reabsorbed by the kidney, resulting
in a dose-dependent increase in urinary
glucose excretion and, ultimately, im-
provement in glycemic parameters (15–
18). Also relevant here are observations
that the renal reabsorptive capacity for
glucose may be increased in patients with
diabetes (19,20). On the basis of these
ﬁndings, we conducted a phase 3 trial of
dapagliﬂozin, administered as mono-
therapy for 24 weeks to treatment-naive
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port results from the study.
RESEARCH DESIGN AND
METHODS— Men and women with
type 2 diabetes, aged 18–77 years, were
enrolled between September 2007 and
July 2008 at 85 sites in the U.S., Canada,
Mexico,andRussia.Eligiblepatientswere
treatment-naivesubjectswhosehypergly-
cemia was inadequately controlled with
diet and exercise alone. Entry criteria in-
cluded BMI 45 kg/m
2 and fasting C-
peptide 1.0 ng/ml. Patients were
excluded if they had a history of type 1
diabetes, serum creatinine 133 mol/l
(men) or 124 mol/l (women), urine
albumin-to-creatinine ratio 200 mg/
mmol, aspartate transaminase and/or ala-
nine transaminase 3 times the upper
limitsofnormal,creatinekinase3times
the upper limit of normal, symptoms of
severely uncontrolled diabetes (including
marked polyuria and polydipsia with
10% weight loss during the last 3
monthsbeforeenrollment);signiﬁcantre-
nal, hepatic, hematological, oncological,
endocrine, psychiatric, or rheumatic dis-
eases, a cardiovascular event (including
New York Heart Association class III/IV
congestive heart failure) within 6 months
of enrollment, and severe uncontrolled
blood pressure (systolic blood pressure
180mmHgand/ordiastolicbloodpres-
sure 110 mmHg).
Thiswasa24-weekrandomized,par-
allel-group, double-blind, placebo-
controlled phase 3 trial with a 2-week
diet/exercise placebo lead-in (1 week for
patients with enrollment A1C 10.1–
12.0%). The respective institutional re-
view board or independent ethics
committee approved the study protocol,
and all patients gave informed consent.
Patients with A1C 7.0–10% were ran-
domly assigned equally to one of seven
arms to receive once-daily placebo or 2.5,
5, or 10 mg dapagliﬂozin, administered
once daily either in the morning (main
cohort) or evening (exploratory cohort)
for 24 weeks. Patients with A1C 10.1–
12% (high-A1C exploratory cohort) were
assignedrandomlyina1:1ratiotoreceive
blinded treatment with a morning dose of
5 or 10 mg/day dapagliﬂozin (a placebo
group was not included because of the
high A1C levels). Patients with fasting
plasma glucose (FPG) 270 mg/dl at
week 4, 240 mg/dl at week 8, or 200
mg/dl at weeks 12–24 were eligible for
open-labelrescuemedication(500mgmet-
formin, titrated as needed up to 2,000 mg).
Patients with A1C 8.0% for 12 weeks de-
spite a maximum tolerated metformin dose
were discontinued. Throughout the study,
patients received diet/exercise counseling
per American Diabetes Association
recommendations.
End points and assessments
The primary efﬁcacy end point was
change from baseline in A1C at week 24
in the main patient cohort. Secondary ef-
ﬁcacy measures included change from
baseline at week 24 in FPG and body
weight. Efﬁcacy measures assessed in the
exploratory evening dose and high-A1C
cohorts included change from baseline at
Figure 1—Patient disposition.
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For patients requiring rescue medication,
data obtained after rescue were excluded
from efﬁcacy analyses. Fractional renal
glucose excretion was calculated as the
ratio of urine to plasma glucose multi-
plied by the ratio of plasma to urine
creatinine.
Safety assessments included vital
signs, laboratory measurements, and ad-
verseevents(codedusingpreferredterms
of the Medical Dictionary for Regulatory
Activites [MedDRA version 11.1]). In ad-
dition, at each visit, patients were actively
monitored for clinical signs and symp-
tomssuggestiveofurinarytractinfections
(UTIs) and genital infections. UTIs and
genital infections are reported here as an
adverse event of special interest and in-
clude any of the prospectively deﬁned 20
preferred terms relating to possible upper
UTI events, 44 preferred terms relating to
possible non–upper UTI events, and 49
preferred terms relating to possible geni-
talinfections(includingbacterialandmy-
cotic infections). Patients were instructed
to self-monitor their blood glucose daily
and to report any unusually high or low
blood glucose event or any symptoms
suggestive of hypoglycemia.
Statistical analysis
Analyses of change from baseline in
A1C, FPG, and body weight were per-
formed using an ANCOVA with treat-
ment group as effect and baseline value
as covariate. Point estimates and 95%
CI were calculated for the mean change
from baseline within each treatment
group as well as for the difference in
mean change from baseline between
treatment groups. Per the study design,
no P values were generated for end
points in exploratory cohorts.
RESULTS— A total of 485 patients
were randomly assigned to the main
morning dose and exploratory evening
dose cohorts (Fig. 1). In addition, 74
patients were randomly assigned to the
exploratory, high-A1C cohort, of which
73 patients took at least one dose of
study medication. Demographic and
baseline characteristics are shown in
Table 1.
In the main cohort, mean A1C reduc-
tions were dose ordered and apparent by
week 4 and maintained thereafter (Fig.
2A). Mean A1C reductions from baseline
at week 24 in the main cohort ranged
from 0.58 to 0.89% with dapagliﬂo-
zin compared with 0.23% with pla-
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signiﬁcantwith5and10mgdapagliﬂozin
(P  0.0005 and P  0.0001, respec-
tively, vs. placebo). At the end of study, a
higher proportion of patients in dapagli-
ﬂozin arms reached the American Diabe-
tes Association/European Association for
the Study of Diabetes target A1C of 7%
(41, 44, and 51% with 2.5, 5, and 10 mg
dapagliﬂozin, respectively, vs. 32% with
placebo).
Reductions in FPG were apparent as
early as week 1. Throughout the study,
FPG reductions were more marked in 5
and 10 mg dapagliﬂozin arms and were
statistically signiﬁcant at week 24 (Fig.
2B,Table2).Meanbodyweightdecreases
were greater with all dapagliﬂozin doses
than with placebo, although they did
not reach statistical signiﬁcance (Fig.
3C, Table 2).
In the exploratory evening dose co-
hort, changes from baseline in A1C, FPG,
and body weight at week 24 were similar
to those seen in the main patient cohort
(Table 2). In the exploratory high-A1C
cohort (10.1–12% at enrollment), treat-
ment with dapagliﬂozin for 24 weeks led
tonumericallygreaterreductionsinmean
A1C and FPG from baseline than those
observed in other cohorts (Table 2). Sub-
group analyses of the main patient cohort
by baseline A1C were consistent with the
ability of dapagliﬂozin to cause greater
A1C reductions in patients with high
baseline A1C. In patients with baseline
A1C 9%, changes in mean A1C from
baseline at week 24 were 1.23  0.98,
1.98  0.90, and 1.90  0.79% with
2.5, 5, and 10 mg dapagliﬂozin groups,
respectively, compared with 0.16 
2.50% with placebo.
Treatment with dapagliﬂozin did not
result in any clinically meaningful
changes from baseline in serum electro-
lytes including serum sodium (Table 2).
There were no clinically relevant changes
inanyrenalfunctionparameterincluding
serum creatinine, blood urea nitrogen, or
cystatinC.Inaddition,therewerenoclin-
ically relevant changes in mean serum al-
bumin with dapagliﬂozin treatment.
Small, numerical decreases from baseline
in high-sensitivity C-reactive protein
(placebo-subtracted adjusted mean
change from baseline value [SE] ranged
from 1.53 [1.06] to 2.67 [1.10] mg/l)
and serum uric acid were observed in
most dapagliﬂozin arms. Small, dose-
orderedmeanincreasesinhematocrit(up
to 2.4%) were observed with dapagliﬂo-
zin. A decrease in mean seated blood
Figure2—Changesinglycemicparametersovertime.A:MeanchangefrombaselineinA1Cafter
adjustment for baseline value. B: Mean change from baseline in FPG after adjustment for baseline
value.C:Meanchangefrombaselineinbodyweightafteradjustmentforbaselinevalue.Errorbars
represent 95% CIs.
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thostatichypotensionwasobservedinthe
dapagliﬂozin arms (Table 2). Rates of hy-
potension/dehydration/hypovolemia
were similar among placebo and dapagli-
ﬂozin arms. Treatment with dapagliﬂozin
did not alter the lipid proﬁle of patients,
although small numerical increases in
HDL cholesterol were noted in all dapa-
gliﬂozin arms (placebo-subtracted ad-
justed mean change from baseline value
[SE] ranged from 0.02 [0.07] to 0.17
[0.08] mmol/l).
Glucose-to-creatinine ratios were
higher with dapagliﬂozin than with pla-
cebo (Table 2). Higher values with the
eveningdosepresumablyreﬂectthephar-
macokinetic half-life of dapagliﬂozin. In
pooled data from the morning and
eveningcohorts,changesfrombaselinein
fractional renal glucose excretion at week
24 were signiﬁcantly related (r  0.13,
P  0.008) with the corresponding
changes in body weight, such that across
all study arms greater renal glucose losses
wereassociatedwithlargerdecrementsin
body weight. A similar trend was found
for changes in glucose excretion and
changes in A1C (P  0.11).
Adverse events are summarized in
Table 3. There was one death due to a
motor vehicle accident in the 10 mg
dapagliﬂozin group. There were no ma-
jor episodes of hypoglycemia in this
study, and none of the patients discon-
tinued the study medication due to hy-
poglycemia. An increased incidence in
signs and symptoms and other reports
suggestive of UTIs and genital infec-
tionswasnotedwithdapagliﬂozintreat-
ment. Safety data in the exploratory
evening dose cohort were similar to
those in the morning dose cohort. A
small number of patients (n  6) expe-
rienced nocturia with the evening dose
(one, two, and three patients in the 2.5,
5 or 10 mg dapagliﬂozin evening dose
arms, respectively, and none with the
morningdose).Therewerenootherno-
table differences in the number or type
of adverse events reported with the
evening dose.
CONCLUSIONS— Administration
of dapagliﬂozin as monotherapy to treat-
ment-naive patients with type 2 diabetes
resulted in clinically meaningful de-
creasesinA1CandFPG,alongwithfavor-
able effects on weight, blood pressure,
and other metabolic parameters. Al-
thoughthedecreaseinbodyweightinour
study did not reach statistical signiﬁcance
compared with placebo, dapagliﬂozin
treatment did lead to increased renal glu-
cose excretion. This glucose excretion
persisted for the full 24-week study pe-
riod and was consistent with the urinary
loss of 200–300 calories/day as re-
ported previously (17). A factor that may
have lessened the effect of dapagliﬂozin
on weight was the large placebo effect in
this study, which was probably due to a
greater impact of diet/exercise counseling
on motivated patients with newly diag-
nosed diabetes in a clinical trial setting. It
should also be noted that the progressive
decrease in weight over time had not
reached a plateau by the end of study;
thus, long-term studies are needed to
morepreciselygaugetheeffectofdapagli-
ﬂozin on weight in the monotherapy set-
ting.Furthermore,inexploratoryanalysis
of pooled data greater increments in frac-
tional renal glucose excretion were asso-
ciated with greater decrements in body
weight, suggesting a link between the
mechanism of action of dapagliﬂozin and
clinical outcome.
Data from the high-A1C cohort are of
particular relevance given the mechanism
Table 3—Adverse events
Placebo
Primary cohort Exploratory cohorts
Dapagliﬂozin morning dose Dapagliﬂozin evening dose
Dapagliﬂozin
morning dose
(A1C 10.1)#
2.5 mg 5 mg 10 mg 2.5 mg 5 mg 10 mg 5 mg 10 mg
n 75 65 64 70 67 68 76 34 39
AEs
At least one AE 45 (60.0) 41 (63.1) 37 (57.8) 48 (68.6) 45 (67.2) 44 (64.7) 45 (59.2) 27 (79.4) 28 (71.8)
At least one serious AE 3 (4.0) 0 1 (1.6) 1 (1.4) 1 (1.5) 1 (1.5) 1 (1.3) 0 0
Discontinuation for AE 1 (1.3) 2 (3.1) 3 (4.7) 5 (7.1) 0 4 (5.9) 3 (3.9) 0 0
Discontinuation for serious AE 0 0 1 (1.6) 0 0 1 (1.5) 1 (1.3) 0 0
Most common AEs (10% in any group)
by MedDRA preferred term*
Nasopharyngitis 4 (5.3) 7 (10.8) 3 (4.7) 2 (2.9) 7 (10.4) 5 (7.4) 4 (5.3) 4 (11.8) 4 (10.3)
Diarrhea 1 (1.3) 4 (6.2) 1 (1.6) 1 (1.4) 3 (4.5) 7 (10.3) 3 (3.9) 2 (5.9) 1 (2.6)
Headache 5 (6.7) 5 (7.7) 3 (4.7) 4 (5.7) 3 (4.5) 9 (13.2) 9 (11.8) 5 (14.7) 6 (15.4)
Events by special interest category
Hypoglycemia† 2 (2.7) 1 (1.5) 0 2 (2.9) 1 (1.5) 0 1 (1.3) 1 (2.9) 0
Events suggestive of UTIs‡ 3 (4.0) 3 (4.6) 8 (12.5) 4 (5.7) 5 (7.5) 8 (11.8) 5 (6.6) 3 (8.8) 6 (15.4)
Events suggestive of genital infections§ 1 (1.3) 5 (7.7) 5 (7.8) 9 (12.9) 6 (9.0) 3 (4.4) 2 (2.6) 2 (5.9) 7 (17.9)
Hypotensive events 1 (1.3) 0 0 1 (1.4) 3 (4.5) 0 0 1 (2.9) 1 (2.6)
Data are n (%) and include data after rescue. *Additional adverse events (AEs) with 5% incidence in any of the primary cohort and exploratory evening dose arms
were arthralgia, pharyngitis, upper respiratory infection, UTI, back pain, dizziness, constipation, inﬂuenza, myalgia, peripheral edema, pain in extremity, and
insomnia. †None of the hypoglycemic events led to discontinuation from the study, and none was a major episode, deﬁned as a symptomatic episode requiring
third-partyassistanceduetosevereimpairmentinconsciousnessorbehavior,withacapillaryorplasmaglucosevalue54mg/dl,andpromptrecoveryafterglucose
or glucagon administration. ‡These events included signs, symptoms, and other reports suggestive of UTIs. §These events included signs, symptoms, and other
reports suggestive of genital infections. #Not placebo controlled.
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hibitor. Patients with high A1C at enroll-
ment are likely already to present with
glycosuria as their ﬁltered glucose load
mayexceedtheabsorptioncapacityofthe
kidney. However, dapagliﬂozin was able
to elicit a considerable improvement in
glycemia in the exploratory high-A1C co-
hort. Results from subgroup analysis of
patients with baseline A1C 9% were
also consistent with the observation that
dapagliﬂozin continues to be efﬁcacious
in patients who present with higher A1C
levels.
There were no major episodes of hy-
poglycemia in this study. After prospec-
tively deﬁned monitoring (see RESEARCH
DESIGN AND METHODS), signs and symptoms
suggestive of UTIs and genital infections
were more frequently reported in the
dapagliﬂozin arms. The reported signs/
symptoms/events of UTIs and genital in-
fections resolved with standard care and
rarely led to discontinuation.
The decrease in mean systolic and di-
astolic blood pressure noted in this study
is in keeping with the diuretic effect of
dapagliﬂozin.Alsoconsistentwiththisef-
fect is the increase in hematocrit levels
noted in the dapagliﬂozin arms. In addi-
tion to blood pressure, favorable, albeit
small, effects were also noted in several
other clinical parameters including HDL
cholesterol,uricacid,andhigh-sensitivity
C-reactive protein. Although effects on
weight, blood pressure, and other meta-
bolic risk factors were small, they may
have a cumulative beneﬁt in the long
term.
Mostnotably,loweringofplasmaglu-
cose with dapagliﬂozin is accompanied
by a urinary loss of calories, suggesting a
shift toward negative net energy balance.
This effect of dapagliﬂozin is unlike that
of other antidiabetic agents, which often
cause weight gain as they lower plasma
glucoseconcentrations.Givenitseffecton
net energy balance and its insulin-
independent mechanism, dapagliﬂozin is
likely to have beneﬁcial effects in a wide
spectrum of patients with diabetes
(17,18).
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